The wider availability of electronic health data, medical registries, and even larger proprietary datasets means that sponsors can now create stronger regulatory submissions by utilizing advanced quantitative methods for historical borrowing. A natural question arises as to which clinical trial designs will best allow sponsors to utilize such datasets.
Since the use of historical data is often a strategic choice to overcome low patient samples or bolster scenarios with underpowered interim results, it is important to ensure that a clinical trial’s statistical design can make the most flexible use of new Bayesian methodologies for historical borrowing. Essential to this is the use of trial software like East Bayes® which ensures that trials are enabled for new methods of historical borrowing.
In Bayesian statistics, when a posterior distribution has the same mathematical form as a prior distribution, then the prior distribution is called a conjugate prior. Such conjugate priors enable probability distributions to “play nice” with the likelihood function.1 In the case of historical borrowing, this means that the historical dataset can be integrated into the new analysis in a relatively straightforward way, without the need for approximations that can affect results and introduce bias.
As an example, in situations where the endpoint is categorical, such as in the form of a response rate, one way to try to ensure that sponsors are working with probabilities where the prior and posterior probability distributions will be conjugate is to simply test out different Beta-distribution functions and determine which are the best for the current trial and related datasets. In principle, only a small number of situations will meet this requirement; they are highly unlikely in real life situations.
Therefore, it is also necessary to use Markov Chain Monte Carlo Methods to generate approximate conjugate priors, where actual conjugate priors are not possible. This requires access to higher-than-normal levels of computing power, but new platforms like East Bayes makes this possible.
Endnotes:
1 John K. Kruschke, Doing Bayesian Data Analysis, 2nd ed. (London: Elsevier, 2011).
Subscribe to our newsletter
Pantelis Vlachos
Vice President, Customer Success
Pantelis is Vice President of Customer Success for our software business and is based in Geneva. Before joining Cytel in 2013, he was a Principal Biostatistician at Merck Serono and a Professor of Statistics at Carnegie Mellon University for 12 years.
His research interests lie in adaptive designs, mainly from a Bayesian perspective, as well as hierarchical model testing and checking, although his secret passion is Text Mining. He has served as Managing Editor of the journal “Bayesian Analysis” as well as on editorial boards of several other journals and online statistical data and software archives.
Pantelis has a PhD in Statistics from the University of Connecticut.
Read full employee bioClaim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.